Eledon Pharmaceuticals (ELDN) stock price is $2.26, up 4.40% on the day, as of Oct 20, 2026. It has a market cap of $257.38Mn, and is classified in the Biotechnology industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap257.38 Mn
P/E-2.72
Div. Yield0.00
Add ratio to table…
About
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company that focuses on developing therapies that modulate the CD40 Ligand pathway. Its lead product candidate tegoprubart is an engineered IgG1 antibody designed to bind CD40L with high affinity while avoiding Fcγ receptor engagement that can cause platelet activation. By blocking CD40L tegoprubart inhibits both CD40 and CD11 costimulatory signaling pathways, which may improve efficacy compared to anti CD40…
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company that focuses on developing therapies that modulate the CD40 Ligand pathway. Its lead product candidate tegoprubart is an engineered IgG1 antibody designed to bind CD40L with high affinity while avoiding Fcγ receptor engagement that can cause platelet activation. By blocking CD40L tegoprubart inhibits both CD40 and CD11 costimulatory signaling pathways, which may improve efficacy compared to anti CD40 receptor approaches. The antibody also promotes regulatory T cell polarization, creating a more tolerogenic immune environment that may benefit transplant recipients and patients with autoimmune or neurodegenerative conditions. Eledon is advancing tegoprubart for the prevention of rejection in kidney transplantation, for xenotransplantation procedures involving genetically modified pig organs, for islet cell transplantation in type 1 diabetes and for the treatment of amyotrophic lateral sclerosis. The company has received orphan drug designation from the FDA for tegoprubart in both amyotrophic lateral sclerosis and islet cell transplantation, underscoring the rarity of those indications and providing potential regulatory benefits. All of these programs are currently in various stages of clinical testing, with no product yet approved for commercial sale.
Eledon Pharmaceuticals Inc has not yet commercialized any product and therefore does not generate revenue from product sales. The company finances its operations primarily through public and private equity offerings, proceeds from the acquisition of Anelixis Therapeutics and potential collaboration payments or milestone fees from partners such as eGenesis. In September 2020 Eledon acquired Anelixis which owned the intellectual property related to tegoprubart, a transaction that provided the company with the antibody and associated patents. Since that acquisition Eledon has raised additional capital through registered direct offerings and private placements to fund its clinical programs. The company also entered into a non exclusive collaborative research agreement with eGenesis in January 2023 under which eGenesis received access to tegoprubart for preclinical and clinical xenotransplantation studies, which may generate future milestone or royalty payments. Until a product receives regulatory approval and reaches market, the primary source of cash flow remains external financing and collaboration related inflows.
The immunosuppression and ALS therapeutic markets are served by large established companies such as Roche Pfizer Biogen and Sanofi as well as numerous specialty biotechnology firms. In the transplant immunosuppression space the standard of care relies heavily on calcineurin inhibitors such as tacrolimus and cyclosporine, which are associated with nephrotoxicity hypertension new onset diabetes and neurologic side effects. Eledon Pharmaceuticals Inc distinguishes itself through its focus on the CD40L pathway and its proprietary antibody tegoprubart which is engineered to reduce the risk of thrombotic events seen with earlier anti CD40L agents. The company’s antibody avoids Fcγ receptor binding, a design feature intended to mitigate platelet activation and thromboembolic complications that limited the development of first generation anti CD40L therapies. Clinical data from Eledon’s Phase 1b and Phase 2 BESTOW studies show that tegoprubart can maintain kidney function with an estimated glomerular filtration rate in the high sixty range, which is numerically higher than the historical average of approximately fifty three mL/min/1.73 m2 reported for tacrolimus based regimens. In ALS the approved drugs riluzole and edaravone offer modest survival benefits, leaving a significant unmet need for disease modifying therapies. Eledon’s orphan drug designation for tegoprubart in ALS provides a potential pathway to market exclusivity if the drug demonstrates efficacy and safety. The combination of a differentiated mechanism, a favorable safety profile and regulatory incentives positions Eledon as a competitive entrant in both transplantation immunology and neurodegenerative disease treatment.
The company’s intended customers include transplant centers and hospitals that perform kidney xenotransplantation and islet cell transplantation procedures, as well as neurologists and treatment centers that care for patients with amyotrophic lateral sclerosis. In the United States there are hundreds of transplant programs that conduct thousands of kidney transplants each year, creating a substantial base of potential users for a novel immunosuppression agent. Eledon Pharmaceuticals Inc also works with academic collaborators and research organizations such as eGenesis Inc and the University of Chicago Medicine to advance its clinical programs, and these partners may become early adopters if the drug receives approval. Should its therapies receive authorization, the end users will be patients receiving transplanted organs or cells and individuals living with ALS who seek therapies that avoid the metabolic and neurologic burdens of current standard of care. The company also engages with patient advocacy groups and clinical trial networks to raise awareness and facilitate enrollment in its studies.
Sector:HealthcareSector rationaleEledon Pharmaceuticals is a clinical-stage biotechnology company developing tegoprubart, an engineered antibody for kidney transplantation and ALS treatment. Its business model is centered on the discovery and clinical testing of medical therapies, which falls squarely within the Biotechnology and Pharmaceuticals industries of the Healthcare sector.Industry:BiotechnologyBiotechnologyPrimaryEledon Pharmaceuticals is a clinical-stage biotechnology company developing tegoprubart, which is an engineered IgG1 antibody. Its business model focuses on biology-based drug discovery and development for indications such as kidney transplantation and ALS.Classified using BQ-MICSCIK: 0001404281
Bull & bear
Investment Thesis
▲ Bull case
Eledon Pharmaceuticals is positioned to benefit from a strategic collaboration with NewcelX that could unlock significant value by combining its anti-CD40L monoclonal antibody tegoprubart with stem-cell-derived islet therapy NCEL-101, targeting a potential functional cure for Type 1 Diabetes. This partnership leverages Eledon's extensive clinical experience from over 100 transplant patients treated with tegoprubart across kidney, heart, and diabetes-related transplant settings, providing robust safety and immunologic data that could de-risk the development of NCEL-101. The collaboration is designed to address a critical bottleneck in cell replacement therapies—immune-mediated graft rejection—by using tegoprubart to modulate T-cell activation pathways, thereby enhancing the durability and survival of implanted islets. This mechanistic synergy could lead to superior clinical outcomes compared to monotherapy approaches, potentially accelerating regulatory discussions and enabling a clearer path to pivotal trials. Given the high unmet need in Type 1 Diabetes and the limitations of current insulin therapy and immunosuppression regimens, a successful combination could capture substantial market share in a rapidly evolving regenerative medicine landscape. The collaboration may also serve as a validation of tegoprubart's broader utility beyond transplant rejection, expanding its addressable market into autoimmune diseases and cell therapy adjuncts. Furthermore, the partnership reduces Eledon's reliance on a single indication by diversifying its pipeline through external innovation, while potentially granting access to milestone payments, royalties, or co-promotion rights if the program advances successfully. The involvement of experienced leadership from both companies, including NewcelX's CSO Professor Michel Revel and CEO Ronen Twito, underscores a disciplined execution focus aimed at translating scientific promise into clinical and commercial milestones.
Eledon Pharmaceuticals is positioned to benefit from a strategic collaboration with NewcelX that could unlock significant value by combining its anti-CD40L monoclonal antibody tegoprubart with stem-cell-derived islet therapy NCEL-101, targeting a potential functional cure for Type 1 Diabetes. This partnership leverages Eledon's extensive clinical experience from over 100 transplant patients treated with tegoprubart across kidney, heart, and diabetes-related transplant settings, providing robust safety and immunologic data that could de-risk the development of NCEL-101. The collaboration is designed to address a critical bottleneck in cell replacement therapies—immune-mediated graft rejection—by using tegoprubart to modulate T-cell activation pathways, thereby enhancing the durability and survival of implanted islets. This mechanistic synergy could lead to superior clinical outcomes compared to monotherapy approaches, potentially accelerating regulatory discussions and enabling a clearer path to pivotal trials. Given the high unmet need in Type 1 Diabetes and the limitations of current insulin therapy and immunosuppression regimens, a successful combination could capture substantial market share in a rapidly evolving regenerative medicine landscape. The collaboration may also serve as a validation of tegoprubart's broader utility beyond transplant rejection, expanding its addressable market into autoimmune diseases and cell therapy adjuncts. Furthermore, the partnership reduces Eledon's reliance on a single indication by diversifying its pipeline through external innovation, while potentially granting access to milestone payments, royalties, or co-promotion rights if the program advances successfully. The involvement of experienced leadership from both companies, including NewcelX's CSO Professor Michel Revel and CEO Ronen Twito, underscores a disciplined execution focus aimed at translating scientific promise into clinical and commercial milestones.
Eledon Pharmaceuticals faces substantial risks in its collaboration with NewcelX, as the partnership remains in an early preclinical/research phase with no guarantee of clinical success, despite optimistic forward-looking statements about accelerating timelines and regulatory pathways. The collaboration depends on the successful integration of two complex biological modalities—stem-cell-derived islets and immune modulation—each of which carries inherent scientific, manufacturing, and safety challenges that may not be fully mitigated by tegoprubart's transplant experience. There is no evidence that immune modulation with anti-CD40L alone will prevent rejection of allogeneic stem-cell-derived islets, particularly given the potential for innate immune activation, inflammation, or epitope spreading that could undermine graft survival despite T-cell targeting. Furthermore, the long-term safety of tegoprubart, particularly regarding thrombotic events associated with historical CD40L inhibitors, remains a concern that could limit dosing or duration in a chronic autoimmune setting like Type 1 Diabetes, where patients may require years of therapy. The market may be overestimating the near-term commercial potential of this collaboration, as NCEL-101 is still years away from potential approval, and Eledon's tegoprubart lacks pivotal data in diabetes-specific transplant or autoimmune contexts beyond exploratory use. Additionally, the competitive landscape in Type 1 Diabetes cell therapy is intensifying, with multiple companies pursuing similar strategies using different immune protection approaches (e.g., encapsulation, checkpoint inhibitors, or Treg induction), which could diminish the perceived differentiation of the Eledon-NewcelX approach. Financially, Eledon may incur significant R&D costs without near-term revenue offset, especially if the collaboration requires additional manufacturing process development, toxicology studies, or clinical bridging trials not yet disclosed. Finally, the reliance on forward-looking statements from NewcelX's press release—including claims about establishing a "well-defined regulatory pathway"—should be viewed skeptically, as no formal regulatory engagement has been announced, and the path to approval for combination cell therapy and immunomodulatory products remains undefined and highly uncertain.
Eledon Pharmaceuticals faces substantial risks in its collaboration with NewcelX, as the partnership remains in an early preclinical/research phase with no guarantee of clinical success, despite optimistic forward-looking statements about accelerating timelines and regulatory pathways. The collaboration depends on the successful integration of two complex biological modalities—stem-cell-derived islets and immune modulation—each of which carries inherent scientific, manufacturing, and safety challenges that may not be fully mitigated by tegoprubart's transplant experience. There is no evidence that immune modulation with anti-CD40L alone will prevent rejection of allogeneic stem-cell-derived islets, particularly given the potential for innate immune activation, inflammation, or epitope spreading that could undermine graft survival despite T-cell targeting. Furthermore, the long-term safety of tegoprubart, particularly regarding thrombotic events associated with historical CD40L inhibitors, remains a concern that could limit dosing or duration in a chronic autoimmune setting like Type 1 Diabetes, where patients may require years of therapy. The market may be overestimating the near-term commercial potential of this collaboration, as NCEL-101 is still years away from potential approval, and Eledon's tegoprubart lacks pivotal data in diabetes-specific transplant or autoimmune contexts beyond exploratory use. Additionally, the competitive landscape in Type 1 Diabetes cell therapy is intensifying, with multiple companies pursuing similar strategies using different immune protection approaches (e.g., encapsulation, checkpoint inhibitors, or Treg induction), which could diminish the perceived differentiation of the Eledon-NewcelX approach. Financially, Eledon may incur significant R&D costs without near-term revenue offset, especially if the collaboration requires additional manufacturing process development, toxicology studies, or clinical bridging trials not yet disclosed. Finally, the reliance on forward-looking statements from NewcelX's press release—including claims about establishing a "well-defined regulatory pathway"—should be viewed skeptically, as no formal regulatory engagement has been announced, and the path to approval for combination cell therapy and immunomodulatory products remains undefined and highly uncertain.